This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Humana (HUM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Humana (HUM) closed at $449.55 in the latest trading session, marking a +0.44% move from the prior day.
5 HMO Stocks Set to Gain From Membership Growth, M&A Strategy
by Debasmita Chatterjee
Rising membership and a rapidly growing aging U.S. population are likely to drive the performances of the Zacks Medical-HMO industry players. UNH, ANTM, HUM, CNC and SEM are poised to benefit from improved operational efficiencies.
Why Is Humana (HUM) Down 1.5% Since Last Earnings Report?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Humana (HUM) Expands JV, To Invest $1.2B, Eyes 100 New Clinics
by Zacks Equity Research
Through the first JV, Humana (HUM) and its partner are pumping $800 million into developing 67 facilities by early 2023.
UnitedHealth (UNH) Unit Chosen to Aid Missouri Medicaid Members
by Zacks Equity Research
UnitedHealth Group's (UNH) unit, UnitedHealthcare, has been selected by Missouri and entrusted to administer the MO HealthNet Managed Care Program to serve the state's Medicaid beneficiaries.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
Cigna (CI) Q1 Earnings Beat on High Membership, Ups '22 EPS View
by Zacks Equity Research
Cigna's (CI) first-quarter results gain momentum from strong performances in Evernorth and Cigna Healthcare segments. A raised EPS outlook for 2022 remains noteworthy.
Ensign Group (ENSG) Down 5.1% Despite Q1 Earnings Beat
by Zacks Equity Research
Ensign Group's (ENSG) first-quarter results highlight sound contributions from the Skilled Services and Standard Bearer segments, partly offset by a rise in expenses mainly stemming from a higher cost of services.
3 Great Stocks to Buy in May and Hold During the Market Selloff
by Benjamin Rains
Investors with long-term outlooks might consider using the current selloff and fear as a chance to buy strong stocks they plan to hold for some extended period of time. The three stocks we look at today also offer solid value, dividends, and are set to grow rather steadily in the coming years.
Community Health (CYH) Q1 Earnings Beat, Trims '22 EPS View
by Zacks Equity Research
Community Health's (CYH) first-quarter results benefit on the back of higher adjusted admissions and reduced interest expense. A lowered 2022 outlook for EPS might be a concern for investors.
Humana (HUM) Q1 Earnings Beat on Solid Healthcare Services
by Zacks Equity Research
Humana (HUM) still has $2 billion remaining under its share repurchase authorization.
Humana (HUM) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 17.72% and 1.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Humana (HUM) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Humana (HUM) Gears Up For Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Humana's (HUM) first-quarter earnings are likely to reflect the impacts of elevated costs related to investments in technology advancements, partly offset by higher premiums in the Retail segment and sound membership growth.
Is First Trust Capital Strength ETF (FTCS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FTCS
Earnings Preview: Humana (HUM) Q1 Earnings Expected to Decline
by Zacks Equity Research
Humana (HUM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cigna (CI) Evernorth Business Ties Up With Kaiser Permanente
by Zacks Equity Research
Cigna (CI) arm Evernorth partners with integrated health care organization Kaiser Permanente to offer better care to Kaiser members.
Ensign Group (ENSG) Ups Credit Facility to $600M to Fuel Growth
by Zacks Equity Research
Ensign Group (ENSG) expands its credit facility by $250 million to continue with its series of acquisitions, renovation of projects, business requirements et al.
Zacks.com featured highlights include Humana, Boise Cascad, Expeditors International of Washington, Cross Country Healthcare, and Olympic Steel
by Zacks Equity Research
Humana, Boise Cascad, Expeditors International of Washington, Cross Country Healthcare, and Olympic Steel are part of Screen of the Week article.
5 Top-Ranked Stocks to Play DuPont Analysis
by Sanghamitra Saha
Have more faith in DuPont analysis than simple ROE calculation? Bet on these five stocks, namely, HUM, BCC, EXPD, CCRN and ZEUS.
Esperion's (ESPR) Drug Sales and Cost-Cutting Drive Stock YTD
by Zacks Equity Research
Esperion's (ESPR) stock rallies so far this year on higher product sales in the fourth quarter of 2021. Cost-saving initiatives to boost margins in 2022 are another key drivers.
The Joint (JYNT) Buys Northern California Regional Developer Zone
by Zacks Equity Research
The Joint (JYNT) expects the Northern California region to hold 75 clinics, including its right to oversee 56 franchisee clinics.
Select Medical (SEM) to Open 31-Bed Hospital in Northern Ohio
by Zacks Equity Research
The new facility is likely to be a satellite unit of Select Medical Holdings' (SEM) Regency Hospital Toledou, located in Sylvania, OH.
Looking for a Growth Stock? 3 Reasons Why Humana (HUM) is a Solid Choice
by Zacks Equity Research
Humana (HUM) possesses solid growth attributes, which could help it handily outperform the market.
UnitedHealth (UNH) to Spend $5.4B on Home-Health Profile Boost
by Zacks Equity Research
UnitedHealth (UNH) intends to combine its Optum business with LHC Group to expand its reach in the healthcare-at-home market.